Cleerly Secures $106M for AI-Enhanced Heart Disease Tool with Medicare Support

Cleerly's AI technology is a groundbreaking tool for the detection of heart disease, employing a sophisticated system that creates a 3D model of coronary arteries from coronary computed tomography angiography (CCTA) images[1]. This FDA-approved technology is designed to assess plaque build-ups and evaluate the risk of oxygen supply disruption to the heart, thereby helping to diagnose coronary artery disease more effectively[2]. Importantly, Cleerly's system, validated through multi-center trials, has been recognized for its high accuracy in evaluating vessel conditions, surpassing the capabilities of medical experts[1]. This innovative tool significantly reduces reliance on invasive testing and is poised to improve treatment strategies through advanced plaque analysis techniques[1][2].